HDAC1 and ataxia telangiectasia: Although the use of more selective HDAC1 inhibitors and the addition of animal experiments remain challenges, our results support the possibility that the combination treatment of CI-994 with etoposide deserves further attention as a therapeutic option for pediatric AT/RT.